A double-blind placebo-controlled study in children showed codergocrine mesylate to be effective in improving cognitive functions and behavioural symptoms associated with learning disorders. Forty randomly grouped children of either sex were given an increasing dosage of codergocrine mesylate and followed up for 12 weeks. A significant improvement was noted in speech (acquisition of new words, comprehensibility/meaningfulness of speech), sociability, attention/concentration, comprehension and memory. Improvement in behaviour (emotional lability and cooperativeness) was also noted. Problems of assessing cognitive progress in very young children with culturally appropriate methods were encountered.
McCarthyPWConnollyJAO'BoyleC: The effect of Hydergine on children with attentional deficit–a preliminary report. Br J Clin Pract1981 (suppl); 47–51.
2.
SykesDIDouglasIWeissG: Attention in hyperactive children and the effect in children of methylphenidate (Ritalin). J Child Psychol Psychiatry1971; 12: 129–139.
3.
LoewDMBuerkiHRCowardDM: Behavioural pharmacology of ergot alkaloids. In: Aging Brain and Ergot Alkaloids (AgnoliA, ed). New York: Raven Press, 1983; pp 227–239.
4.
ChierichettiSCucinottaDSantiniV. In: Aging 2000: Our Health Care Destiny, Vol. 1, Biomedical Issues (GaitzCMSamorajskiT, eds). New York: Springer, 1985; pp 377–393.
5.
ShaderRIHarmatzJSTammerkH-A: Towards an observational structure for rating dysfunction and pathology in ambulatory geriatrics. In: CNS Aging and Its Neuropharmacology (Meier-RugeW, ed). Basle: S. Karger, 1979; pp 153–168.
6.
BanenDM: An ergot preparation (Hydergine) for relief of symptoms of cerebrovascular insufficiency. J Am Ger Soc1972; 20: 22–24.
7.
GaitzCMVarnerRVOverallJE: Pharmacotherapy for organic brain syndrome in later life; evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry1977; 34: 839–845.
8.
YesavageJARushL: Senile dementia: combined pharmacologic and psychologic treatment. J Am Ger Soc1981; 29: 164–171.
9.
DravidAR: Deficits in cholinergic enzyme and muscarinic receptors in the hippocampus and striatum of senescent rats. Effects of chronic Hydergine treatment. Arch Int Pharmacodyn Ther1983; 264: 195–202.
10.
MatejcekMBlasowitschRSchweingruberM: Some correlations in geriatric patients between EEG parameters and clinical status. Neuropsychobiology1986; 15: 49–56.
11.
GaitzCMHartfordJT: Ergot alkaloids in treatment of geriatric patients with dementia. In: Geriatic Psychopharmacology, Vol 3 (NandyK, ed). Amsterdam: Elsevier/North Holland, 1979; pp 213–224.
12.
HollingsworthSW: Response of geriatric patients to Hydergine therapy. Curr Ther Res1980; 27: 401–410.
13.
OswaldWDDennlerHJ: Drugs and Methods in Cerebrovascular Disease. Proceedings of an International Symposium on Acute and Chronic CVD, Paris, 1980. New York: Pergamon Press, 1981; pp 351–357.
14.
WittenbornID: Pharmacotherapy for age-related behavioural deficiencies. J Nerv Ment Dis1981; 169: 139–156.
15.
WechslerD: Manual for the Wechsler Intelligence Scale for Children. New York: The Psychological Corporation, 1974.
16.
EmeneggerHMeier-RugeW: The actions of Hydergine on the brain. Pharmacology1968; 1: 65.
